# Patient-Trial Match Report

*Generated: 2026-01-05 18:33:41*

## Patient Profile

- **Age**: 42
- **Sex**: Male
- **Cancer Type**: NSCLC
- **Biomarkers**: ALK rearrangement

**Clinical Description**:
> 42-year-old male with ALK-rearranged metastatic NSCLC (EML4-ALK variant 1). CNS-dominant disease with multiple brain metastases (>10 lesions, largest 2.1cm) and leptomeningeal enhancement on MRI. Systemic disease stable on alectinib x18 months but clear CNS progression. Prior crizotinib x8 months. No WBRT yet - oncology preference to avoid if possible. Mild headaches, no focal neurological deficits. CSF cytology positive for malignant cells. Seeking trials with enhanced CNS penetration or leptomeningeal disease focus. Otherwise healthy, never smoker.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 10
- **Total trials evaluated**: 90
- **Excluded by fast filter**: 27
- **LLM scored**: 63

## ðŸŸ  LOW Likelihood (3 trials)

### [NCT03851445](https://clinicaltrials.gov/study/NCT03851445)

**LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)**

- **Sponsor**: SWOG Cancer Research Network
- **Phase**: Phase 2/Phase 3
- **Status**: Recruiting
- **Confidence**: 30%

**âœ“ Supporting Factors:**
- Male
- Age: 42
- Cancer type: NSCLC (non-small cell lung cancer)
- Biomarkers: ALK rearrangement
- ECOG status: 1
- Prior therapies: crizotinib, alectinib

**âœ— Potential Conflicts:**
- Brain metastases: active - trial criteria may exclude patients with significant brain metastases.

**? Uncertainties:**
- Must confirm adequacy of tumor tissue and whether a fresh biopsy is needed.
- CSF cytology positive for malignant cells may complicate eligibility depending on trial interpretation of CNS disease.

**Assessment:**
> The patient's cancer type matches the trial's focus on NSCLC, but significant uncertainties exist regarding eligibility, particularly concerning active brain metastases, which may lead to exclusion.

---

### [NCT05384626](https://clinicaltrials.gov/study/NCT05384626)

**A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)**

- **Sponsor**: Nuvalent Inc.
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Age >= 18 years
- Histologically or cytologically confirmed metastatic NSCLC with documented ALK rearrangement

**âœ— Potential Conflicts:**
- Active brain metastases could be a concern regarding eligibility based on organ function/therapy criteria
- Patient is currently experiencing CNS progression with multiple brain metastases which may not qualify for trials focused on CNS penetration
- Prior therapies including crizotinib and alectinib conflicts with the trial's treatment line requirements if marked as first-line or treatment-naive

**? Uncertainties:**
- Adequate organ function and bone marrow reserve specifics are not provided
- The implications of the current treatment preference by the oncology team (avoiding WBRT and ongoing CNS complications) need further clarity

**Assessment:**
> The patient's cancer type matches the trial, but significant concerns about current disease status (active brain metastases) and prior treatment history suggest substantial barriers to eligibility, leading to a low likelihood of matching.

---

### [NCT04899908](https://clinicaltrials.gov/study/NCT04899908)

**A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone**

- **Sponsor**: Dana-Farber Cancer Institute
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 20%

**âœ“ Supporting Factors:**
- Age: 42
- Sex: male
- Cancer type: NSCLC
- Biomarkers: ALK rearrangement
- ECOG status: 1

**âœ— Potential Conflicts:**
- Patient has active brain metastases and widespread definitive leptomeningeal disease, which is an exclusion criterion.

**? Uncertainties:**
- Estimated glomerular filtration rate is not provided.
- Estimated survival based on extracranial disease is not provided.
- Ability to understand and willingness to sign informed consent is not provided.

**Assessment:**
> The patient's condition is NSCLC, which matches the trial's focus on lung cancer, but the active brain metastases with widespread definitive leptomeningeal disease conflict with the exclusion criteria. This significantly affects eligibility. Uncertainties regarding organ function and estimated survival further lower the confidence in eligibility.

---

## Excluded (87 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT06717334](https://clinicaltrials.gov/study/NCT06717334) | Patient age 42 is below minimum age 50 |
| [NCT02143830](https://clinicaltrials.gov/study/NCT02143830) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05058651](https://clinicaltrials.gov/study/NCT05058651) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05313243](https://clinicaltrials.gov/study/NCT05313243) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05684965](https://clinicaltrials.gov/study/NCT05684965) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06388564](https://clinicaltrials.gov/study/NCT06388564) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06404086](https://clinicaltrials.gov/study/NCT06404086) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06582745](https://clinicaltrials.gov/study/NCT06582745) | Patient age 42 is above maximum age 30 |
| [NCT06730750](https://clinicaltrials.gov/study/NCT06730750) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07013474](https://clinicaltrials.gov/study/NCT07013474) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07023731](https://clinicaltrials.gov/study/NCT07023731) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT07275216](https://clinicaltrials.gov/study/NCT07275216) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT00001352](https://clinicaltrials.gov/study/NCT00001352) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03420963](https://clinicaltrials.gov/study/NCT03420963) | Patient age 42 is above maximum age 40 |
| [NCT04245397](https://clinicaltrials.gov/study/NCT04245397) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04423029](https://clinicaltrials.gov/study/NCT04423029) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04474301](https://clinicaltrials.gov/study/NCT04474301) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05022446](https://clinicaltrials.gov/study/NCT05022446) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05701657](https://clinicaltrials.gov/study/NCT05701657) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06145763](https://clinicaltrials.gov/study/NCT06145763) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 7 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT05501665](https://clinicaltrials.gov/study/NCT05501665) | Vanderbilt-Ingram Ca | Patient has active brain metastases that cannot be managed with surgery or stereotactic radiosurgery prior to initiation of treatment, as required for eligibility. |
| [NCT05715229](https://clinicaltrials.gov/study/NCT05715229) | Hackensack Meridian  | Patient has prior systemic therapy (crizotinib and alectinib) while trial is for treatment-naive patients. |
| [NCT05853575](https://clinicaltrials.gov/study/NCT05853575) | Mirati Therapeutics  | Patient has NSCLC with ALK rearrangement, while trial requires KRAS G12C mutation. |
| [NCT06074588](https://clinicaltrials.gov/study/NCT06074588) | Merck Sharp & Dohme  | Has known active central nervous system metastases and/or carcinomatous meningitis, which is an exclusion criteria |
| [NCT06246110](https://clinicaltrials.gov/study/NCT06246110) | Eikon Therapeutics | Patient has received prior systemic therapies (crizotinib, alectinib), whereas trial criteria exclude patients who have received prior systemic treatment for advanced/metastatic NSCLC. |
| [NCT06712316](https://clinicaltrials.gov/study/NCT06712316) | BioNTech SE | Patient has ALK rearrangement; trial excludes NSCLC with ALK rearrangement. |
| [NCT06788912](https://clinicaltrials.gov/study/NCT06788912) | Merck Sharp & Dohme  | Patient has active brain metastases which conflict with inclusion criteria of having resectable NSCLC. |
| [NCT07216404](https://clinicaltrials.gov/study/NCT07216404) | Alan Davis | Patient has active brain metastases, which is significant CNS pathology excluding criteria. |
| [NCT07063745](https://clinicaltrials.gov/study/NCT07063745) | Bristol-Myers Squibb | Prior systemic therapy for metastatic disease (crizotinib and alectinib) conflicts with the requirement for no prior systemic anti-cancer therapy for metastatic disease. |
| [NCT00897117](https://clinicaltrials.gov/study/NCT00897117) | Vanderbilt-Ingram Ca | The trial requires clinical stage I and II disease, but the patient has metastatic NSCLC. |
| [NCT03551951](https://clinicaltrials.gov/study/NCT03551951) | University of Missou | Trial requires patients with resectable solid cancers; patient has active brain metastases and CNS-dominant disease, which generally indicates unresectable status. |
| [NCT05415358](https://clinicaltrials.gov/study/NCT05415358) | Wake Forest Universi | Patient has prior therapies (crizotinib, alectinib) but this trial requires patients who have completed at least 20 months of first-line immunotherapy, which the patient has not received. |
| [NCT05430009](https://clinicaltrials.gov/study/NCT05430009) | VA Ann Arbor Healthc | The patient's cancer type is NSCLC, but the trial specifically targets liver metastases, which the patient does not have as per the profile. |
| [NCT05866302](https://clinicaltrials.gov/study/NCT05866302) | University of Michig | The patient has non-small cell lung cancer (NSCLC), while the trial is focused on chronic lung disease and hematopoietic cell transplantation, which does not match the patient's cancer type. |
| [NCT06562192](https://clinicaltrials.gov/study/NCT06562192) | Novartis Pharmaceuti | Patient has active brain metastases, which is typically an exclusion for trials unless specified otherwise. |
| [NCT07176000](https://clinicaltrials.gov/study/NCT07176000) | Fred Hutchinson Canc | Patient has NSCLC, but the trial focuses on the lung cancer screening in specific communities, not specifically targeting treatment for cancer. |
| [NCT07220096](https://clinicaltrials.gov/study/NCT07220096) | M.D. Anderson Cancer | Patient has prior therapies (crizotinib and alectinib), indicating he is not treatment-naive |
| [NCT07008664](https://clinicaltrials.gov/study/NCT07008664) | University of Maryla | Patient has NSCLC (ALK-rearranged), but the trial is focused on diagnosing lung cancer and does not specify eligibility for particular lung cancer subtypes. |
| [NCT04665206](https://clinicaltrials.gov/study/NCT04665206) | Vivace Therapeutics, | Patient has active brain metastases which are explicitly excluded from the trial. |
| [NCT05443126](https://clinicaltrials.gov/study/NCT05443126) | Ellipses Pharma | Patient has NSCLC with ALK rearrangement which is not mentioned as eligible for this trial that focuses on RET-altered malignancies. |
| ... | ... | *and 40 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| ALK rearrangement | manual | 1.0 |
| ALKrearrangement | manual | 0.9 |
| ALK-rearrangement | manual | 0.9 |
| NSCLC | manual | 1.0 |
| ALK rearrangement NSCLC | manual | 1.0 |
| ALK rearrangement non-small cell lung cancer | llm | 0.9 |
| NSCLC ALK rearrangement | llm | 0.9 |
| non-small cell lung cancer | llm | 0.8 |
| lung cancer | llm | 0.8 |
| EML4-ALK variant 1 | llm | 0.9 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
